theophylline has been researched along with ticlopidine in 15 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (13.33) | 18.7374 |
1990's | 2 (13.33) | 18.2507 |
2000's | 1 (6.67) | 29.6817 |
2010's | 10 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Buccino, G; Cocciolo, M; Colli, A; Elli, GM; Parravicini, R; Scaltrini, G | 1 |
Andriani, A; Chiappetta, MG; Fabiani, M | 1 |
Caplain, H; Necciari, J; Thebault, JJ | 1 |
Fitzgerald, DJ; Quinn, MJ | 1 |
Farid, NA; Hagihara, K; Ikeda, T; Ishizuka, T; Kazui, M; Kurihara, A; Nishiya, Y; Okazaki, O | 1 |
Camenisch, G; Chibale, K; Huth, F; Njuguna, NM; Schiller, H; Umehara, KI | 1 |
Brooks, MB; Divers, TJ; Hernandez, D; Ness, SL; Stokol, T; Yeo, WM | 1 |
3 review(s) available for theophylline and ticlopidine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Platelet aggregation and antiaggregant drugs].
Topics: Dipyridamole; Humans; Papaverine; Platelet Aggregation; Prostaglandins; Theophylline; Thiophenes; Thromboxane A2; Ticlopidine; Verapamil | 1982 |
Ticlopidine and clopidogrel.
Topics: Adenosine Diphosphate; Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Angina, Unstable; Aspirin; Bone Marrow Diseases; Carbamazepine; Cardiovascular Diseases; Clopidogrel; Combined Modality Therapy; Coronary Disease; Drug Interactions; Hemorrhage; Humans; Myocardial Infarction; Peripheral Vascular Diseases; Phenytoin; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Safety; Stents; Theophylline; Thrombolytic Therapy; Ticlopidine | 1999 |
2 trial(s) available for theophylline and ticlopidine
Article | Year |
---|---|
Clopidogrel does not affect the pharmacokinetics of theophylline.
Topics: Administration, Oral; Adult; Clopidogrel; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Drug Interactions; Humans; Male; Microsomes, Liver; Platelet Aggregation; Platelet Aggregation Inhibitors; Theophylline; Ticlopidine | 1999 |
Effects of various antiplatelet drugs on ex vivo platelet activation induced by equine herpesvirus type 1.
Topics: Animals; Aspirin; Clopidogrel; Cross-Over Studies; Double-Blind Method; Female; Flow Cytometry; Herpesviridae Infections; Herpesvirus 1, Equid; Horse Diseases; Horses; Male; Pentoxifylline; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Theophylline; Ticlopidine | 2016 |
10 other study(ies) available for theophylline and ticlopidine
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Ticlopidine-theophylline interaction.
Topics: Adult; Drug Interactions; Humans; Kinetics; Male; Metabolic Clearance Rate; Theophylline; Ticlopidine | 1987 |
Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.
Topics: Antibodies; Aryl Hydrocarbon Hydroxylases; Biocatalysis; Biotransformation; Cell Line; Cell Line, Tumor; Clopidogrel; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Glutathione; Humans; Ketoconazole; Kinetics; Mephenytoin; Microsomes; Microsomes, Liver; NADP; Omeprazole; Oxidation-Reduction; Oxidoreductases, N-Demethylating; Platelet Aggregation Inhibitors; Sulfaphenazole; Theophylline; Ticlopidine | 2010 |
Improvement of the chemical inhibition phenotyping assay by cross-reactivity correction.
Topics: Acetates; Cyclopropanes; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Humans; Ketoconazole; Phenotype; Quinidine; Quinolines; Sulfaphenazole; Sulfides; Theophylline; Ticlopidine | 2016 |